QVT buys Biosynexus

Biosynexus, a biotechnology-pharmaceutical company that is commercializing a portfolio of products for the prevention and treatment of infectious diseases, has been acquired for an unspecified sum by the QVT Fund. Biosynexus also announced that Dr. Irwin Scher has been appointed CEO. "It is very exciting to be joining a company with such tremendous potential, and to be coming on board with QVT Fund LP as our parent company," said Dr. Scher. "This will provide us with the additional capital for completing our clinical trials and for further investment in, and expansion of, our current pipeline."

- read this press release for more

Suggested Articles

Robertson, M.D., who led global development teams within Shire’s neuroscience division, is now Yumanity Therapeutics’ chief medical officer.

Novo Nordisk and Dicerna are teaming up on liver-related diseases, including nonalcoholic steatohepatitis (NASH), to the tune of $225 million.

After announcing it was slashing scores of jobs, Alkermes is now willing to put down nearly $1 billion to buy out CNS biotech Rodin Therapeutics.